PTC Therapeutics Reports 47% Revenue Growth to $225.6 Million in Q1 2026

PTC Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net product revenue of $225.6 million, a significant increase of 47% compared to $153.4 million in the same period last year. This growth was primarily driven by the sales of Sephience, a treatment for phenylketonuria (PKU), which generated $124.6 million in net sales during its first year of launch. However, the company experienced a decline in sales from its other products, including Emflaza and Translarna, attributed to increased competition and regulatory challenges.

The company's total revenues for the quarter amounted to $272.6 million, a decrease from $1.2 billion in the previous year, largely due to a one-time recognition of $989.8 million in collaboration and license revenue from the Novartis Agreement in Q1 2025. For the current quarter, collaboration and license revenue was minimal at $0.1 million. Royalty revenue also saw an increase, reaching $46.8 million, up from $36.4 million, reflecting higher sales of Evrysdi, a treatment for spinal muscular atrophy.

Operating expenses for the quarter totaled $227.6 million, up from $205.9 million in the prior year. This increase was driven by higher costs associated with product sales and increased amortization of acquired intangible assets, which rose to $11.6 million from $3.8 million. Research and development expenses decreased to $100.9 million from $109.0 million, reflecting a strategic focus on high-potential programs. Selling, general, and administrative expenses also increased to $86.2 million, up from $81.0 million, as the company continued to invest in its commercial infrastructure.

As of March 31, 2026, PTC Therapeutics reported an accumulated deficit of approximately $2.97 billion and a cash position of $834 million, down from $985 million at the end of 2025. The company anticipates that its existing cash, along with projected revenues from product sales and milestone payments, will be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for significant revenue generation to achieve and sustain profitability, and may require additional funding through equity offerings, debt financing, or collaborations.

Looking ahead, PTC Therapeutics is focused on advancing its product pipeline, including ongoing clinical trials for its splicing and inflammation programs. The company is also preparing for the potential commercialization of Sephience in various markets, while navigating the challenges posed by regulatory changes and market competition for its existing products.